Skip to main content

David Tabernero Caellas

Institutions of which they are part

Senior researcher
Liver Diseases
Vall Hebron Institut de Recerca

David Tabernero Caellas

Institutions of which they are part

Senior researcher
Liver Diseases
Vall Hebron Institut de Recerca

Projects

Complejidad de la cuasiespecie del virus de la Hepatitis B en las regiones X, precore y core: Asociación con la severidad de la infección

IP: Francisco Rodríguez Frias
Collaborators: Clara Ramírez Serra, Lluis Castells Fusté, Silvia Camòs Anguila, Rafael Esteban Mur, David Tabernero Caellas
Funding agency: Instituto de Salud Carlos III
Funding: 98373
Reference: PI12/01893
Duration: 01/01/2013 - 31/03/2016

Prevalencia de las quasispecies mutantes en antígeno de superficie en paceintes con hepatitis crónica B y trasplantados por hepatitis B

IP: Maria Buti Ferret
Collaborators: Rafael Esteban Mur, Andrea Caballero Garralda, David Tabernero Caellas
Funding agency: Instituto de Salud Carlos III
Funding: 275715.44
Reference: PI11/01973
Duration: 01/01/2012 - 28/02/2015

Análisis de la cuasispecie viral en la infección por virus de la hepatitis B: evolución natural yu asociada al tratamiento antiviral

IP: Francisco Rodríguez Frias
Collaborators: Maria Buti Ferret, David Tabernero Caellas
Funding agency: Instituto de Salud Carlos III
Funding: 90750
Reference: PI09/00899
Duration: 01/01/2010 - 31/12/2012

Unitat de Recerca en Malalties Hepatobiliars

IP: Joan Genescà Ferrer
Collaborators: Immaculada Raurell Saborit, Antonio González Fernández, Lluis Castells Fusté, Francisco Rodríguez Frias, Silvia Sauleda Oliveras, Lluís Palenzuela Díaz, Victor Manuel Vargas Blasco, Maria Buti Ferret, Josep Quer Sivila, Maria Nieves Martell Pérez-Alcalde, Rafael Esteban Mur, Juan Ignacio Esteban Mur, David Tabernero Caellas
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 54080
Reference: 2009 SGR 383
Duration: 01/01/2010 - 30/04/2014

Related news

Preliminary study results confirm that the drug resmetirom reduces the presence of fat, inflammation, cell damage and fibrosis in the liver.

The European project, in which Vall d'Hebron participates, will favor personalized diagnosis and innovative therapeutic strategies in patients with the disease.

The research team used nanotechnology to deliver the drug directly to liver cells, which eliminated side effects without reducing effectiveness.

Related professionals

Rosa Mejon Berges

Rosa Mejon Berges

Read more
Carmen Simon-Talero Peña

Carmen Simon-Talero Peña

Research Group of Physical Medicine and Rehabilitation
Read more
Albert Barberà LLuis

Albert Barberà LLuis

Director/a d'Àrea
Core Facilities Area
Read more
Emma Bigas Alsina

Emma Bigas Alsina

Research technician
Liver Diseases
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.